Microsoft word - soap note instructions for student providers 11-08
SOAP Note Instructions for Student Providers
Please type your SOAP note in Word. See other side for sample SOAP note format.
Use hyphens (-) instead of slashes (/) or backslashes (\) whenever possible (due to
built-in macros in Carecast). Using the forward slash (/) with BP readings, dates, orother numbers is OK.
Do not use tabs or tables. Keep the format simple and easy to read.
Include the following information at the top of your note:
PATIENT: Jane SmithMRN: 0123456ENCOUNTER DATE: 01-04-07
Please spell out and capitalize the words SUBJECTIVE, OBJECTIVE, ASSESSMENT, and
PLAN with each new section (do not abbreviate with S, O, A, or P). You may combine theASSESSMENT and PLAN or type them separately.
If you address more than one problem in your assessment and/or plan, you may number the
items sequentially (see other side for example).
Type the following sentence at the end of the note regarding the attending provider who
Dr. ___________ was present for and participated in the care of this patient.
Include your name, medical program, and year in the program at the bottom of the note:
For example, Patient seen by Jane Doe, M2.
If you use an interpreter during the patient encounter, also type the following at the end of
Interpretation by ___________, bilingual student.
Also, list names/disciplines (e.g., PT, nutrition, pharmacy, dental, etc.) of other students
Once the attending provider has read your note and approved it, please inform the
student administrator who will copy and paste your note into the patient's medical record.
Be sure to delete the original Word file from the computer.
This is a 66 year old Hispanic female patient with diabetes mellitus who presents for follow up of difficultybreathing and med refills. Patient was seen on January 2, 2007 for difficulty breathing. She was sent to
the ER at UNMC for further examination; however, the ER workup was essentially non diagnostic. ABGwas ordered after her ER visit and was normal except for PCO2 of 34 (35-45). The only new problem is a
headache (frontal and bilateral) for 2 days, only in the morning. Patient describes the pain as “a lot ofpressure”, 4/10. She denies nausea or vomiting, aura, photosensitivity, dizziness, change in visual acuity,or pain in the eyes. No URI sx. She has no trouble sleeping and has good appetite. She denies any pain
other than her AM headaches. She denies falling episodes or paresthesia. She was accompanied by hergrandson tonight who told us that the patient’s family thinks her problem is “somewhat psychological.”
They noticed that she has no breathing problems while she is sleeping or talking. Her last eye exam was2 months ago.
Current Medications:Lipitor 10 mg 1 tab po daily
Glipizide 5 mg 1 tab po bidLisinopril 10 mg 1 tab po dailyMetformin 500 mg 2 tabs po bid
Hydrochlorothiazide 12.5 mg po dailyMeclizine 12.5 mg 1 tab po tid prn
Nexium 40 mg 1 tab po dailyLancets and test strips
The patient states that she understands the Rx regimens and takes the medications regularly. Herdaughter checks the patient’s Rx.
OBJECTIVE:Vitals: Wt 140lb, Ht 5’2”, BP 131/79 (Lt arm, regular cuff), T 97.9F oral, P 88, R 24
Gen: Patient appears her stated age, negative for jaundice. Negative depression screen.
Head: NC/AT, no bruits. No tenderness upon percussion of frontal and maxillary sinuses.
Nose: Pink moist nasal mucosa, not edematous or erythematous.
Eyes: PERRLA, NVA cc, OU.
Heart: RRR c 3/6 systolic murmur heard best at LLSBLungs: CTA
ASSESSMENT/PLAN:1. Diabetes mellitus controlled with her current Rxs, which were refilled. Glycohemoglobin ordered.
2. Hypertension: good control, refill Rxs.
3. Idiopathic tachypnea: the patient was advised to return to the clinic if the symptom worsens.
4. Headache: follow-up next visit.
Dr. John Smith was present for and participated in the care of this patient.
Patient seen by John Doe, M2 and Jane Nutritious, Dietetic Intern. Interpretation by Sal y Gonzales,bilingual student.
Phosphodiesterase Type 5 Inhibitor Use and Hearing Impairment Objective: To compare use of phosphodiesterase type Results: The overall prevalence of self-reported hearing 5 inhibitors (PDE-5i) between participants with and with-impairment and PDE-5i use in each group was 17.9% andout self-reported hearing impairment using logistic2%, respectively. Men who reported hearing impairmentre
Regulatory Toxicology and Pharmacology 47 (2007) 78–83Risk assessment for glucosamine and chondroitin sulfate ଝ Council for Responsible Nutrition, 1828 L Street, NW, Suite 900, Washington, DC 20036-5114, USA Abstract Glucosamine and chondroitin sulfate are two popular dietary ingredients present in dietary supplements intended to support jointhealth. A large body of human and anim